Potential Impact of Interventions to Enhance Retention in Care During Real-World HIV Pre-Exposure Prophylaxis Implementation

被引:17
|
作者
Chan, Philip A. [1 ,2 ]
Goedel, William C. [3 ]
Nunn, Amy S. [2 ]
Sowemimo-Coker, Genoviva [1 ]
Galarraga, Omar [4 ]
Prosperi, Mattia [5 ]
Patel, Rupa [6 ]
Mena, Leandro [7 ]
Montgomery, Madeline C. [1 ]
Marshall, Brandon D. L. [3 ]
机构
[1] Brown Univ, Dept Med, 1125 North Main St, Providence, RI 02904 USA
[2] Brown Univ, Dept Behav & Social Sci, Providence, RI 02912 USA
[3] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA
[4] Brown Univ, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA
[5] Univ Florida, Dept Epidemiol, Gainesville, FL USA
[6] Washington Univ, Dept Med, St Louis, MO USA
[7] Univ Mississippi, Dept Populat Hlth Sci, Jackson, MS 39216 USA
关键词
HIV; prevention; PrEP; MSM; agent-based modeling; MEN; SEX; PREVENTION; INFECTION; RISK; ADHERENCE;
D O I
10.1089/apc.2019.0064
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Pre-exposure prophylaxis (PrEP) has the potential to significantly reduce HIV incidence among men who have sex with men (MSM) in the United States. However, the extent to which suboptimal PrEP adherence and retention in care may limit successful implementation is unknown. An agent-based model was used to represent the entire population of MSM in Rhode Island from 2013 to 2017. The impact of potential interventions to improve PrEP adherence and retention in care on HIV transmission was evaluated. Demographics, behaviors, and PrEP adherence and retention in care rates were based on local clinical data. We assumed that 20% of HIV-negative MSM had ever taken PrEP. The primary outcome was HIV incidence over the 5-year period. The model included 23,815 MSM with an estimated 4.1% HIV prevalence based on local surveillance data. An estimated 173.1 new infections occurred over 5 years [95% simulation interval (SI): 171.5-174.7], including 29.1 new infections among individuals who had ever initiated PrEP (95% SI: 28.6-29.7). Interventions that improved retention in PrEP care by an odds of 5.0 compared with the base case maximized reductions in HIV incidence among MSM who had ever initiated PrEP by 37.5%. Interventions focusing on improving PrEP adherence had little to no effect on HIV incidence, regardless of intervention efficacy. Retention in care is a critical component of the PrEP care continuum. Interventions that improve retention in PrEP care may lead to greater reductions in population-level HIV incidence compared with interventions focused exclusively on adherence.
引用
收藏
页码:434 / 439
页数:6
相关论文
共 50 条
  • [1] Real-world safety of pre-exposure prophylaxis for HIV
    Burns, Charles M.
    Wyatt, Christina
    [J]. LANCET HIV, 2022, 9 (04): : E225 - E226
  • [2] Pre-Exposure Prophylaxis for HIV Can It Be Implemented in the Real World?
    Katz, Mitchell H.
    [J]. AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2013, 44 (01) : S161 - S162
  • [3] IMPLEMENTATION OF AN HIV PRE-EXPOSURE PROPHYLAXIS STRATEGY INTO ABORTION CARE
    Sonalkar, S.
    Fishman, J.
    Kete, C.
    McAllister, A.
    Frarey, A.
    Short, W. R.
    Schreiber, C. A.
    Teitelman, A.
    [J]. CONTRACEPTION, 2021, 104 (04) : 450 - 450
  • [4] Time to Make the Jump: Translating HIV Pre-exposure Prophylaxis Research Into Real-World Public Health Impact
    Patel, Rupa R.
    Chan, Philip A.
    Mena, Leandro
    Crowley, Jeffrey S.
    McCoy, Katryna
    Nunn, Amy
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 75 (05) : E144 - E146
  • [5] Real-World Eligibility for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs
    Jonathan Picard
    Brendan Jacka
    Stine Høj
    Émélie Laverdière
    Joseph Cox
    Élise Roy
    Julie Bruneau
    [J]. AIDS and Behavior, 2020, 24 : 2400 - 2408
  • [6] Real-World Eligibility for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs
    Picard, Jonathan
    Jacka, Brendan
    Hoj, Stine
    Laverdiere, Emelie
    Cox, Joseph
    Roy, Elise
    Bruneau, Julie
    [J]. AIDS AND BEHAVIOR, 2020, 24 (08) : 2400 - 2408
  • [7] How to Identify Potential Candidates for HIV Pre-Exposure Prophylaxis: An AI Algorithm Reusing Real-World Hospital Data
    Duthe, Jean-Charles
    Bouzille, Guillaume
    Sylvestre, Emmanuelle
    Chazard, Emmanuel
    Arvieux, Cedric
    Cuggia, Marc
    [J]. PUBLIC HEALTH AND INFORMATICS, PROCEEDINGS OF MIE 2021, 2021, 281 : 714 - 718
  • [8] Pre-exposure HIV prophylaxis: the world is waiting
    不详
    [J]. LANCET, 2012, 379 (9835): : 2402 - 2402
  • [9] Oral HIV pre-exposure prophylaxis use among pregnant and postpartum women: results from real-world implementation in Lesotho
    Masenyetse, Lieketseng J.
    Greenberg, Lauren
    Samonyane, Felleng
    Sekepe, Bokang
    Mokone, Majoalane
    Mokone, Mafusi J.
    Tukei, Vincent J.
    Beres, Laura K.
    [J]. FRONTIERS IN REPRODUCTIVE HEALTH, 2023, 5
  • [10] Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States
    Adams, Jessica L.
    Shelley, Karishma
    Nicol, Melanie R.
    [J]. PHARMACOTHERAPY, 2019, 39 (04): : 486 - 500